使用髂动脉分支装置行血管内修复髂动脉瘤的前瞻性多中心研究五年结果
该前瞻性多中心研究纳入63例腹主动脉髂动脉瘤或髂总动脉瘤患者,植入单个髂动脉分支腔内移植物及分叉主动脉髂动脉覆膜支架,5年全因死亡豁免率85.7%,动脉瘤相关死亡豁免率100%,髂内动脉分支通畅率95.1%,证实该装置安全有效且持久。
要点
- 5年全因死亡豁免率85.7%,动脉瘤相关死亡豁免率100%。
- 髂内动脉分支和髂外动脉分支一期通畅率分别为95.1%和100%。
- 无Ⅰ型或Ⅲ型内漏及装置移位,二次干预豁免率90.5%。
核心结论
- 5年结果证实该髂动脉分支腔内移植物治疗腹主动脉髂动脉瘤和髂动脉瘤安全、有效且持久。
- 该装置有效预防髂总动脉瘤破裂,维持髂内动脉通畅,避免髂内动脉牺牲相关并发症。
- 髂总动脉瘤增大罕见,但腹主动脉增大更常见,提示伴或不伴髂总动脉瘤患者的血管内动脉瘤修复结局可能不同。
研究设计与样本
- 前瞻性、多中心研究,在美国开展,共纳入63例腹主动脉髂动脉瘤或髂总动脉瘤患者(98.4%为男性,平均年龄70岁)。
- 患者植入单个髂动脉分支腔内移植物(IBE;W.L. Gore & Associates,Flagstaff,AZ)及分叉主动脉髂动脉覆膜支架。
- 双侧髂总动脉瘤患者(n=22;34.9%)在研究入组前已行对侧髂内动脉分期闭塞或外科血运重建。
- 5年时36例完成最终随访检查,包括临床检查(n=35)和计算机断层扫描(n=32),结果由独立核心实验室评估,不良事件由临床事件委员会裁定。
主要发现
- 5年全因死亡豁免率为85.7%,动脉瘤相关死亡豁免率为100%。
- 发生的9例死亡(范围132-1898天)被裁定与动脉瘤或手术无关。
- 髂内动脉和髂外动脉IBE分支一期通畅率分别为95.1%和100%。
- 无患者在IBE侧出现新发臀部跛行或自报新发勃起功能障碍。
- 在基线和5年计算机断层扫描均有的31例患者中,30例(96.8%)IBE侧髂总动脉直径不变或减小≥5 mm;31例可评估患者中9例(29.0%)主动脉直径增加≥5 mm,其中5例合并Ⅱ型内漏。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We have reported the 5-year results of a pivotal prospective, multicenter study conducted in the United States of a specifically designed iliac branch endoprosthesis (IBE; W.L. Gore & Associates, Flagstaff, AZ) for endovascular repair of aortoiliac aneurysms and common iliac artery aneurysms. METHODS: A total of 63 patients (98.4% male; mean age, 70 years) with aortoiliac or common iliac artery aneurysms had undergone implantation of a single IBE device and a bifurcated aortoiliac stent graft. Patients with bilateral common iliac artery aneurysms (n = 22; 34.9%) had undergone either staged occlusion or surgical revascularization of the contralateral internal iliac artery before study enrollment. At 5 years, 36 of the 63 patients had completed the final study follow-up examinations, including clinical examinations (n = 35) and computed tomography (n = 32), with the results evaluated by an independent core laboratory and adverse events adjudicated by a clinical events committee. RESULTS: At 5 years, freedom from all-cause mortality was 85.7% and freedom from aneurysm-related mortality was 100%. The nine deaths that had occurred (range, 132-1898 days) were adjudicated as unrelated to the aneurysm or procedure. Primary patency of the internal and external iliac artery IBE limbs was 95.1% and 100%, respectively. No patients had experienced new-onset buttock claudication on the IBE side or self-reported new-onset erectile dysfunction. The common iliac artery diameter on the IBE side was either unchanged or had decreased by ≥5 mm in 30 of the 31 patients (96.8%) with a baseline (1 month) and 5-year (range, 1641-2006 days) computed tomography scan available. Of the 31 evaluable patients, 9 (29.0%) had had an increase of ≥5 mm in the aortic diameter, 5 of whom had had a concurrent type II endoleak. No type I or type III endoleaks or device migration were identified by the core laboratory. Six patients had undergone eight secondary interventions, including five interventions for a type II endoleak. The freedom from secondary intervention was 90.5%. CONCLUSIONS: The 5-year results of our prospective, multicenter study have confirmed the safety, efficacy, and durability of the IBE device for the treatment of aortoiliac and iliac artery aneurysms. The device effectively prevented common iliac artery aneurysm rupture, maintained the patency of the internal iliac artery, and avoided the complications associated with internal iliac artery sacrifice. Although common iliac artery aneurysm enlargement was rare, abdominal aortic enlargement was more common, suggesting that the outcomes of endovascular aneurysm repair might be different for patients with or without associated common iliac artery aneurysms.
引用
- Schneider DB, Matsumura JS, Lee JT, et al. Five-year outcomes from a prospective, multicenter study of endovascular repair of iliac artery aneurysms using an iliac branch device. J Vasc Surg. 2022. PMID: 35842202. doi:10.1016/j.jvs.2022.07.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。